Insightec reaffirms its position at the forefront of the
medical technology industry with improved functionality, safety
features, and efficiency to its flagship product, setting new
benchmarks in the field with unparalleled achievements.
HAIFA,
Israel and MUNICH, April 16,
2024 /PRNewswire/ -- Insightec, a global healthcare
company dedicated to using acoustic energy to transform patient
care, today announced the CE approval and European launch of
Exablate Prime, a significant enhancement to the Exablate Neuro
platform. Based on customer input and feedback, Exablate Prime is
the culmination of over 10 years of significant research and
development designed to increase precision, efficiency, and
experience of the surgeon – and the patient.
Like its predecessor, Exablate Prime enables incisionless
neurosurgery as an outpatient procedure to provide relief to people
living with movement disorders, such as essential tremor and
Parkinson's disease. New improvements include an enriched user
interface and enhancements to optimize productivity. Specific
improvements include:
- Intuitive user interface: designed with guided
workflows, automated steps, and a streamlined UI
- Automated calculations: Intelligent algorithms for
one-click skull-density-ratio (SDR) calculations,
automatic fusion and AC/PC identification, and efficient no-pass
region detection
- Intuitive and informative therapy delivery:
temperature-driven control enabled by an accurate temperature
prediction algorithm
- Increased specificity and control: Precise
targeting and lesion shaping with sub-millimetric
targeting control and advanced shaping masks
- Real-time monitoring: cumulative thermal dose
overlays
- Enhanced planning & support: improved cyber
security, PACS connectivity, remote planning, and
troubleshooting
- Improved visualization and image management:
automatic MR scan acquisition, intelligent targeting tools,
and larger MR data sets in one planning session
The system also boasts an optional, upgraded 3T head coil for
improved imaging and 3D thermal spot visualization.
"Our unwavering commitment to enhancing patient care through
innovative technology led us to develop Exablate Prime," said
Maurice R. Ferre, M.D., CEO and
chairman of the board of Insightec. "Although Exablate Neuro has
revolutionized the field of neurosurgery, Exablate Prime takes it
to entirely new levels, pushing the boundaries of what is possible.
We couldn't be more proud of the end result – Exablate Prime is the
future of incisionless neurosurgery."
"With the growing number of European countries supporting
focused ultrasound as viable treatment option for essential tremor,
Exablate Prime is truly exciting," commented Giuseppe Carbone, vice president of Insightec
Europe. "We are confident it will make even more of a positive
impact to empower Europeans living with essential tremor and
Parkinson's disease – as well as their physicians."
To ensure Exablate Prime met the needs of working neurosurgeons,
it was tested first in Rambam Hospital in Haifa, Israel where suggestions for
improvement were implemented. It was then tested in the US by
Oregon Health and Science University.
"We were proud to lead the validation pilot study
for Prime and be a design partner with Insightec," said
Dr. Lior Lev Tov, senior
neurosurgeon at Rambam Hospital. We truly appreciate the great
improvements it brings to the treatment."
Exablate Prime is available for sale in the US and
Europe. For more information about
Exablate Prime or to schedule a demonstration, please contact
marketing@insightec.com
About Insightec
Insightec is a global healthcare
company creating the next generation of patient care by realizing
the therapeutic power of acoustic energy. The company's Exablate
Neuro platform focuses sound waves, safely guided by MRI, to
provide tremor treatment to patients with medication-refractory
essential tremor and Parkinson's disease. Research for future
applications in the neuroscience space is underway in partnership
with leading academic and medical institutions. Insightec is
headquartered in Haifa, Israel, and Miami, with
offices in Dallas, Shanghai, and Tokyo.
Forward-looking Statements:
This document contains forward-looking statements regarding,
among other things, plans, expectations, and future events. In some
cases, forward-looking statements can be identified by the
following words: "may," "can," "will," "could," "would," "should,"
"expect," "intend," "plan," "anticipate," "believe," "estimate,"
"predict," "project," "potential," "promise," "continue,"
"ongoing," or the negative of these terms. Forward-looking
statements involve known and unknown risks, uncertainties and other
important factors that could cause actual results to differ
materially from what is expressed or implied by the statements. Any
forward-looking statement is based on information available to
Insightec as of the date of the statement. All written or oral
forward-looking statements attributable to Insightec are qualified
by this caution. Insightec does not undertake any obligation to
update or revise any forward-looking statement to reflect any
change in circumstances or in Insightec's expectations.
"Exablate," and "Exablate Neuro," as well as the "Insightec"
logo, whether standing alone or in connection with the word
"Insightec," are protected trademarks of Insightec.
Photo -
https://mma.prnewswire.com/media/2387752/Insightec_Exablate_Prime_UI.jpg
Photo -
https://mma.prnewswire.com/media/2387753/Insightec_Exablate_Prime_Console.jpg
Photo -
https://mma.prnewswire.com/media/2387754/Insightec_Exablate_Prime.jpg
Logo -
https://mma.prnewswire.com/media/1699588/4650287/Insightec_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/insightec-announces-exablate-prime-availability-in-europe-the-next-generation-of-mr-guided-focused-ultrasound-302118100.html